Title of the Project: BER Inhibitor TRC102 added to Standard Pemetrexed-Platinum- Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer Project Summary/Abstract This application is being submitted to request for an administrative supplement through the P30 CA043703-24 for the approved LOI #10512 (BER Inhibitor TRC102 added to Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer). The Case Comprehensive Cancer Center (Case CCC) has a long track record in conducting early phase clinical trials with a variety of sponsors, including pharmaceutical, physician-investigator and CTEP sponsored studies. Seidman Cancer Center, a member of the Case CCC, enrolls over 120 patients per year in early phase trials. It has a significant infrastructure in place that allows for rapid study activation, patient accrual and enrollment of patients with uncommon genomic abnormalities, minority accrual, quality nursing, and data management. The structure of the phase I program engages physicians from disease sub-specialties. The quality assurance program and regular weekly staff meetings provide internal oversight. Recently the LOI# 10512 was approved by CTEP to open a phase IIR clinical trial through ETCTN. Through the requested administrative supplement (EDDOP), we hope to be able to open and complete the clinical trial with CTEP.
|Effective start/end date
|2/1/87 → 3/31/23
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.